← Eichor
Study identifier: NCT05282732 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients

Condition: Renal Failure · End Stage Renal Disease · Acute Renal Failure  ·  Sponsor: Fresenius Medical Care Deutschland GmbH

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Retrospective analysis of performance and treatment data collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter \& Genius 90 Concentrates in acute haemodialysis, haemodynamically instable patients and chronic haemodialysis patients * to analyse performance and treatment data from patients treated with the investigational device * to evaluate the filter characteristics for aHD (Acute haemodialysis) patients * to evaluate the improvement of kidney function for aHD patients

This description comes directly from the study's public registry record.

Talk to the study team

Tatiana De los Rios  ·  +49 6172 608 2362  ·  Tatiana.De-Los-Rios@fmc-ag.com

Jana Schmitt  ·  +49 6172 609 95403  ·  Jana.Schmitt@fmc-ag.com

Always discuss trial participation with your own doctor first.

Locations (2)

Medizinische Hochschule HannoverHanover, GermanyRecruiting
Universitätsklinikum JenaJena, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05282732